Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vericel Corp (VCEL)
NASDAQ:VCEL
VCEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$39.12 - $63.00
Previous CloseN/A
Volume83.17K
Average Volume (3M)397.87K
Market Cap
$2.82B
Enterprise Value$2.05B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)913.4
Beta1.33
Next Earnings
Feb 27, 2025EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding49,358,410
10 Day Avg. Volume321,889
30 Day Avg. Volume397,866
Standard Deviation0.16
R-Squared0.31
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.42
Price to Cash Flow (P/CF)69.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.14
Enterprise Value/Ebitda196.66
Forecast
1Y Price Target
$66.40Price Target Upside16.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Vericel News
PremiumCompany Announcements
Vericel Projects Strong Growth and Profitability Ahead
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceVCEL has exceeded the consensus revenue projection by an average of 4.2% over the past seven quarters.
Market OutlookThe price target for Vericel Corporation has been increased from $60.00 to $72.00, indicating a positive outlook for the company's stock.
Product LaunchThe recent launch of MACI Arthro represents the next meaningful layer of growth for VCEL.
Bears Say
Market Launch DelaysManagement included an estimated OUS MACI launch in the 'late 2020s' for the first time, ahead of MACI Ankle in 2030+.
ProfitabilityThe anticipated inflection point of net income profitability for FY24 is seen as differentiated at its current revenue run rate, which should provide cash flow generation going forward.
Revenue GuidanceVCEL pre-announced 4Q24 revenue ~3% below consensus and issued 2025 revenue guidance ~2% below consensus at the midpoint.
---
Ownership Overview
0.89% Insiders
35.38% Mutual Funds
0.79% Other Institutional Investors
40.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VCEL FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was $39.12 and its highest was $63.00 in the past 12 months.
What is Vericel Corp’s market cap?
Vericel Corp’s market cap is $2.82B.
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is Feb 27, 2025 which is in 7 days.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on Nov 07, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.048 by $0.028.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is 0.32.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 49,358,410 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.048. Following the earnings report the stock price went up 4.142%.
Which hedge fund is a major shareholder of Vericel Corp?
Currently, no hedge funds are holding shares in VCEL
---
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.40 (16.31% Upside)
$66.40 (16.31% Upside)
Blogger Sentiment
Bullish
VCEL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 23.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.03%
12-Months-Change
Fundamentals
Return on Equity
1.54%
Trailing 12-Months
Asset Growth
22.72%
Trailing 12-Months
Company Description
Vericel Corp
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
---
VCEL Company Deck
---
VCEL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Vericel had a strong third quarter with significant revenue growth, margin expansion, and key regulatory approvals. Despite reporting a net loss and increased operating expenses, the company's financial performance was robust, with strong cash flow and a positive outlook for future growth.Read More>---
VCEL Stock 12 Month Forecast
Average Price Target
$66.40
▲(16.31% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Apyx Medical
―
Sarepta Therapeutics
―
MiMedx Group
―
Organogenesis Holdings
―
Best Analysts Covering VCEL
1 Year
1 Year Success Rate
15/15 ratings generated profit
1 Year Average Return
+32.35%
reiterated a buy rating last month
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +32.35% per trade.
---